Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia

Jean Luc Canon, Johan Vansteenkiste, G. Bodoky, M. Victoria Mateos, Laurent Bastit, Irene Ferreira, Greg Rossi, Rafael G. Amado, G. Stegar, A. Neubauer, W. Aulitzky, C. Peschel, M. Hedenus, S. Hansen, W. Stewrd, B. Emmerich, A. Tomova, V. Malec, N. Frickhofen, J. J. CruzD. Bron, S. Pyrhonen, W. Hilgers, L. Bosquée, M. Clemens, M. R. Nowrousian, F. Nobile, A. H. Honkoop, H. W A Berenschot, M. R. Schaafsma, P. Gascón, A. Gúrpide, E. Kubista, G. V. Kornek, K. Gattringer, J. Van Droogenbroeck, P. Zachee, M. Hansen, C. Aul, A. Hanauske, S. Korsten, G. Wiedemann, P. Marchetti, A. Iop, R. Hermann, D. Rauch, M. Bargetzi, D. W. Milligan, A. Ferrant, K. Van Eygen, U. Jäger, E. Gunsilius, M. Aapro, M. Wilhelm, W. Brugger, E. D. Kreuser, M. J. Eckhart, O. Brudler, B. Anker Jensen, E. Lindegaard Madsen, A. Lozano, A. Alcala, J. Sierra, A. Lopez, J. Mäenpää, L. M. Dourthe, P. Laplaige, D. Castera, E. Antoine, H. P. Eikesdal, S. Barroso, E. Sanches, G. Birgegård, M. H M Kramer, M. R. Schipperus, M. Boogaerts, E. Juvonen, B. Lauri, J. Thaler, P. Sorensen, M. Smakal, P. Koralewski, P. Serwatowski, E. Simova, M. Galova, M. Kuta, M. Wojtukiewicz, M. Kalalejcik, R. Barila, S. Spanik, T. Pintér, G. Bodoky, J. Szántó, K. Leppik, T. Jogi, A. Brize, G. Purkalne, M. Bitina, E. Hotko

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background: In the United States, darbepoetin alfa (Aranesp) is often used to treat patients with chemotherapy-induced anemia using weekly or every-2-week administration schedules. In Europe, darbepoetin alfa is used either weekly or in every-3-week dosing. The every-3-week schedule can be synchronized with many chemotherapy regimens, resulting in fewer visits and reducing burden to patients, but the safety and efficacy of this regimen have not been clear. Methods: A randomized, double-blind, double-dummy, active-controlled phase 3 trial was performed in 110 European centers. Eligible patients (age ≥18 years) were anemic (hemoglobin level

Original languageEnglish
Pages (from-to)273-284
Number of pages12
JournalJournal of the National Cancer Institute
Volume98
Issue number4
DOIs
Publication statusPublished - Feb 15 2006

Fingerprint

Anemia
Drug Therapy
Appointments and Schedules
Patient Safety
Hemoglobins
Therapeutics
Darbepoetin alfa

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. / Canon, Jean Luc; Vansteenkiste, Johan; Bodoky, G.; Mateos, M. Victoria; Bastit, Laurent; Ferreira, Irene; Rossi, Greg; Amado, Rafael G.; Stegar, G.; Neubauer, A.; Aulitzky, W.; Peschel, C.; Hedenus, M.; Hansen, S.; Stewrd, W.; Emmerich, B.; Tomova, A.; Malec, V.; Frickhofen, N.; Cruz, J. J.; Bron, D.; Pyrhonen, S.; Hilgers, W.; Bosquée, L.; Clemens, M.; Nowrousian, M. R.; Nobile, F.; Honkoop, A. H.; Berenschot, H. W A; Schaafsma, M. R.; Gascón, P.; Gúrpide, A.; Kubista, E.; Kornek, G. V.; Gattringer, K.; Van Droogenbroeck, J.; Zachee, P.; Hansen, M.; Aul, C.; Hanauske, A.; Korsten, S.; Wiedemann, G.; Marchetti, P.; Iop, A.; Hermann, R.; Rauch, D.; Bargetzi, M.; Milligan, D. W.; Ferrant, A.; Van Eygen, K.; Jäger, U.; Gunsilius, E.; Aapro, M.; Wilhelm, M.; Brugger, W.; Kreuser, E. D.; Eckhart, M. J.; Brudler, O.; Anker Jensen, B.; Lindegaard Madsen, E.; Lozano, A.; Alcala, A.; Sierra, J.; Lopez, A.; Mäenpää, J.; Dourthe, L. M.; Laplaige, P.; Castera, D.; Antoine, E.; Eikesdal, H. P.; Barroso, S.; Sanches, E.; Birgegård, G.; Kramer, M. H M; Schipperus, M. R.; Boogaerts, M.; Juvonen, E.; Lauri, B.; Thaler, J.; Sorensen, P.; Smakal, M.; Koralewski, P.; Serwatowski, P.; Simova, E.; Galova, M.; Kuta, M.; Wojtukiewicz, M.; Kalalejcik, M.; Barila, R.; Spanik, S.; Pintér, T.; Bodoky, G.; Szántó, J.; Leppik, K.; Jogi, T.; Brize, A.; Purkalne, G.; Bitina, M.; Hotko, E.

In: Journal of the National Cancer Institute, Vol. 98, No. 4, 15.02.2006, p. 273-284.

Research output: Contribution to journalArticle

Canon, JL, Vansteenkiste, J, Bodoky, G, Mateos, MV, Bastit, L, Ferreira, I, Rossi, G, Amado, RG, Stegar, G, Neubauer, A, Aulitzky, W, Peschel, C, Hedenus, M, Hansen, S, Stewrd, W, Emmerich, B, Tomova, A, Malec, V, Frickhofen, N, Cruz, JJ, Bron, D, Pyrhonen, S, Hilgers, W, Bosquée, L, Clemens, M, Nowrousian, MR, Nobile, F, Honkoop, AH, Berenschot, HWA, Schaafsma, MR, Gascón, P, Gúrpide, A, Kubista, E, Kornek, GV, Gattringer, K, Van Droogenbroeck, J, Zachee, P, Hansen, M, Aul, C, Hanauske, A, Korsten, S, Wiedemann, G, Marchetti, P, Iop, A, Hermann, R, Rauch, D, Bargetzi, M, Milligan, DW, Ferrant, A, Van Eygen, K, Jäger, U, Gunsilius, E, Aapro, M, Wilhelm, M, Brugger, W, Kreuser, ED, Eckhart, MJ, Brudler, O, Anker Jensen, B, Lindegaard Madsen, E, Lozano, A, Alcala, A, Sierra, J, Lopez, A, Mäenpää, J, Dourthe, LM, Laplaige, P, Castera, D, Antoine, E, Eikesdal, HP, Barroso, S, Sanches, E, Birgegård, G, Kramer, MHM, Schipperus, MR, Boogaerts, M, Juvonen, E, Lauri, B, Thaler, J, Sorensen, P, Smakal, M, Koralewski, P, Serwatowski, P, Simova, E, Galova, M, Kuta, M, Wojtukiewicz, M, Kalalejcik, M, Barila, R, Spanik, S, Pintér, T, Bodoky, G, Szántó, J, Leppik, K, Jogi, T, Brize, A, Purkalne, G, Bitina, M & Hotko, E 2006, 'Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia', Journal of the National Cancer Institute, vol. 98, no. 4, pp. 273-284. https://doi.org/10.1093/jnci/djj053
Canon, Jean Luc ; Vansteenkiste, Johan ; Bodoky, G. ; Mateos, M. Victoria ; Bastit, Laurent ; Ferreira, Irene ; Rossi, Greg ; Amado, Rafael G. ; Stegar, G. ; Neubauer, A. ; Aulitzky, W. ; Peschel, C. ; Hedenus, M. ; Hansen, S. ; Stewrd, W. ; Emmerich, B. ; Tomova, A. ; Malec, V. ; Frickhofen, N. ; Cruz, J. J. ; Bron, D. ; Pyrhonen, S. ; Hilgers, W. ; Bosquée, L. ; Clemens, M. ; Nowrousian, M. R. ; Nobile, F. ; Honkoop, A. H. ; Berenschot, H. W A ; Schaafsma, M. R. ; Gascón, P. ; Gúrpide, A. ; Kubista, E. ; Kornek, G. V. ; Gattringer, K. ; Van Droogenbroeck, J. ; Zachee, P. ; Hansen, M. ; Aul, C. ; Hanauske, A. ; Korsten, S. ; Wiedemann, G. ; Marchetti, P. ; Iop, A. ; Hermann, R. ; Rauch, D. ; Bargetzi, M. ; Milligan, D. W. ; Ferrant, A. ; Van Eygen, K. ; Jäger, U. ; Gunsilius, E. ; Aapro, M. ; Wilhelm, M. ; Brugger, W. ; Kreuser, E. D. ; Eckhart, M. J. ; Brudler, O. ; Anker Jensen, B. ; Lindegaard Madsen, E. ; Lozano, A. ; Alcala, A. ; Sierra, J. ; Lopez, A. ; Mäenpää, J. ; Dourthe, L. M. ; Laplaige, P. ; Castera, D. ; Antoine, E. ; Eikesdal, H. P. ; Barroso, S. ; Sanches, E. ; Birgegård, G. ; Kramer, M. H M ; Schipperus, M. R. ; Boogaerts, M. ; Juvonen, E. ; Lauri, B. ; Thaler, J. ; Sorensen, P. ; Smakal, M. ; Koralewski, P. ; Serwatowski, P. ; Simova, E. ; Galova, M. ; Kuta, M. ; Wojtukiewicz, M. ; Kalalejcik, M. ; Barila, R. ; Spanik, S. ; Pintér, T. ; Bodoky, G. ; Szántó, J. ; Leppik, K. ; Jogi, T. ; Brize, A. ; Purkalne, G. ; Bitina, M. ; Hotko, E. / Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. In: Journal of the National Cancer Institute. 2006 ; Vol. 98, No. 4. pp. 273-284.
@article{228ac98d9f634b2bab119f63df221c49,
title = "Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia",
abstract = "Background: In the United States, darbepoetin alfa (Aranesp) is often used to treat patients with chemotherapy-induced anemia using weekly or every-2-week administration schedules. In Europe, darbepoetin alfa is used either weekly or in every-3-week dosing. The every-3-week schedule can be synchronized with many chemotherapy regimens, resulting in fewer visits and reducing burden to patients, but the safety and efficacy of this regimen have not been clear. Methods: A randomized, double-blind, double-dummy, active-controlled phase 3 trial was performed in 110 European centers. Eligible patients (age ≥18 years) were anemic (hemoglobin level",
author = "Canon, {Jean Luc} and Johan Vansteenkiste and G. Bodoky and Mateos, {M. Victoria} and Laurent Bastit and Irene Ferreira and Greg Rossi and Amado, {Rafael G.} and G. Stegar and A. Neubauer and W. Aulitzky and C. Peschel and M. Hedenus and S. Hansen and W. Stewrd and B. Emmerich and A. Tomova and V. Malec and N. Frickhofen and Cruz, {J. J.} and D. Bron and S. Pyrhonen and W. Hilgers and L. Bosqu{\'e}e and M. Clemens and Nowrousian, {M. R.} and F. Nobile and Honkoop, {A. H.} and Berenschot, {H. W A} and Schaafsma, {M. R.} and P. Gasc{\'o}n and A. G{\'u}rpide and E. Kubista and Kornek, {G. V.} and K. Gattringer and {Van Droogenbroeck}, J. and P. Zachee and M. Hansen and C. Aul and A. Hanauske and S. Korsten and G. Wiedemann and P. Marchetti and A. Iop and R. Hermann and D. Rauch and M. Bargetzi and Milligan, {D. W.} and A. Ferrant and {Van Eygen}, K. and U. J{\"a}ger and E. Gunsilius and M. Aapro and M. Wilhelm and W. Brugger and Kreuser, {E. D.} and Eckhart, {M. J.} and O. Brudler and {Anker Jensen}, B. and {Lindegaard Madsen}, E. and A. Lozano and A. Alcala and J. Sierra and A. Lopez and J. M{\"a}enp{\"a}{\"a} and Dourthe, {L. M.} and P. Laplaige and D. Castera and E. Antoine and Eikesdal, {H. P.} and S. Barroso and E. Sanches and G. Birgeg{\aa}rd and Kramer, {M. H M} and Schipperus, {M. R.} and M. Boogaerts and E. Juvonen and B. Lauri and J. Thaler and P. Sorensen and M. Smakal and P. Koralewski and P. Serwatowski and E. Simova and M. Galova and M. Kuta and M. Wojtukiewicz and M. Kalalejcik and R. Barila and S. Spanik and T. Pint{\'e}r and G. Bodoky and J. Sz{\'a}nt{\'o} and K. Leppik and T. Jogi and A. Brize and G. Purkalne and M. Bitina and E. Hotko",
year = "2006",
month = "2",
day = "15",
doi = "10.1093/jnci/djj053",
language = "English",
volume = "98",
pages = "273--284",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia

AU - Canon, Jean Luc

AU - Vansteenkiste, Johan

AU - Bodoky, G.

AU - Mateos, M. Victoria

AU - Bastit, Laurent

AU - Ferreira, Irene

AU - Rossi, Greg

AU - Amado, Rafael G.

AU - Stegar, G.

AU - Neubauer, A.

AU - Aulitzky, W.

AU - Peschel, C.

AU - Hedenus, M.

AU - Hansen, S.

AU - Stewrd, W.

AU - Emmerich, B.

AU - Tomova, A.

AU - Malec, V.

AU - Frickhofen, N.

AU - Cruz, J. J.

AU - Bron, D.

AU - Pyrhonen, S.

AU - Hilgers, W.

AU - Bosquée, L.

AU - Clemens, M.

AU - Nowrousian, M. R.

AU - Nobile, F.

AU - Honkoop, A. H.

AU - Berenschot, H. W A

AU - Schaafsma, M. R.

AU - Gascón, P.

AU - Gúrpide, A.

AU - Kubista, E.

AU - Kornek, G. V.

AU - Gattringer, K.

AU - Van Droogenbroeck, J.

AU - Zachee, P.

AU - Hansen, M.

AU - Aul, C.

AU - Hanauske, A.

AU - Korsten, S.

AU - Wiedemann, G.

AU - Marchetti, P.

AU - Iop, A.

AU - Hermann, R.

AU - Rauch, D.

AU - Bargetzi, M.

AU - Milligan, D. W.

AU - Ferrant, A.

AU - Van Eygen, K.

AU - Jäger, U.

AU - Gunsilius, E.

AU - Aapro, M.

AU - Wilhelm, M.

AU - Brugger, W.

AU - Kreuser, E. D.

AU - Eckhart, M. J.

AU - Brudler, O.

AU - Anker Jensen, B.

AU - Lindegaard Madsen, E.

AU - Lozano, A.

AU - Alcala, A.

AU - Sierra, J.

AU - Lopez, A.

AU - Mäenpää, J.

AU - Dourthe, L. M.

AU - Laplaige, P.

AU - Castera, D.

AU - Antoine, E.

AU - Eikesdal, H. P.

AU - Barroso, S.

AU - Sanches, E.

AU - Birgegård, G.

AU - Kramer, M. H M

AU - Schipperus, M. R.

AU - Boogaerts, M.

AU - Juvonen, E.

AU - Lauri, B.

AU - Thaler, J.

AU - Sorensen, P.

AU - Smakal, M.

AU - Koralewski, P.

AU - Serwatowski, P.

AU - Simova, E.

AU - Galova, M.

AU - Kuta, M.

AU - Wojtukiewicz, M.

AU - Kalalejcik, M.

AU - Barila, R.

AU - Spanik, S.

AU - Pintér, T.

AU - Bodoky, G.

AU - Szántó, J.

AU - Leppik, K.

AU - Jogi, T.

AU - Brize, A.

AU - Purkalne, G.

AU - Bitina, M.

AU - Hotko, E.

PY - 2006/2/15

Y1 - 2006/2/15

N2 - Background: In the United States, darbepoetin alfa (Aranesp) is often used to treat patients with chemotherapy-induced anemia using weekly or every-2-week administration schedules. In Europe, darbepoetin alfa is used either weekly or in every-3-week dosing. The every-3-week schedule can be synchronized with many chemotherapy regimens, resulting in fewer visits and reducing burden to patients, but the safety and efficacy of this regimen have not been clear. Methods: A randomized, double-blind, double-dummy, active-controlled phase 3 trial was performed in 110 European centers. Eligible patients (age ≥18 years) were anemic (hemoglobin level

AB - Background: In the United States, darbepoetin alfa (Aranesp) is often used to treat patients with chemotherapy-induced anemia using weekly or every-2-week administration schedules. In Europe, darbepoetin alfa is used either weekly or in every-3-week dosing. The every-3-week schedule can be synchronized with many chemotherapy regimens, resulting in fewer visits and reducing burden to patients, but the safety and efficacy of this regimen have not been clear. Methods: A randomized, double-blind, double-dummy, active-controlled phase 3 trial was performed in 110 European centers. Eligible patients (age ≥18 years) were anemic (hemoglobin level

UR - http://www.scopus.com/inward/record.url?scp=33144458077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144458077&partnerID=8YFLogxK

U2 - 10.1093/jnci/djj053

DO - 10.1093/jnci/djj053

M3 - Article

C2 - 16478746

AN - SCOPUS:33144458077

VL - 98

SP - 273

EP - 284

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -